BABY-KILLING VACCINE: IS IT BEING STEALTH TESTED?
by James A. Miller
During the early 1990s, the World Health Organization (WHO) has been
overseeing massive vaccination campaigns against tetanus in a number
of countries, among them Nicaragua, Mexico, and the Philippines. In
October 1994, HLI received a communication from its Mexican
affiliate, the Comite Pro Vida de Mexico, regarding that country's
anti-tetanus campaign. Suspicious of the campaign protocols, the
Comite obtained several vials of the vaccine and had them analyzed by
chemists. Some of the vials were found to contain human chorionic
gonadotrophin (hCG), a naturally occurring hormone essential for
maintaining a pregnancy.
hCG and anti-hCG antibodies
In nature the hCG hormone alerts the women's body that she is
pregnant and causes the release of other hormones to prepare the
uterine lining for the implantation of the fertilized egg. The rapid
rise in hCG levels after conception makes it an excellent marker for
confirmation of pregnancy: when a woman takes a pregnancy test she is
not tested for the pregnancy itself, but for the elevated presence of
However, when introduced into the body coupled with a tetanus toxoid
carrier, antibodies will be formed not only against tetanus but also
against hCG. In this case the body fails to recognize hCG as a friend
and will produce anti-hCG antibodies. These antibodies will attack
subsequent pregnancies by killing the hCG which naturally sustains a
pregnancy; when a woman has sufficient anti-hCG antibodies in her
system, she is rendered incapable of maintaining a pregnancy.
HLI reported the sketchy facts regarding the Mexican tetanus vaccines
to its World Council members and affiliates in more than 60
countries. Soon additional reports of vaccines laced with hCG
hormones began to drift in from the Philippines, where more than 3.4
million women were recently vaccinated. Similar reports came from
Nicaragua, which had conducted its own vaccination campaign in 1993.
The known facts
Here are the known facts concerning the tetanus vaccination campaigns
in Mexico and the Philippines:
* Only women are vaccinated, and only the women between the ages of
15 and 45. (In Nicaragua the age range was 12-49). But aren't men at
least as likely as young women to come into contact with tetanus? And
what of the children? Why are they excluded?
* Human chorionic gonadotrophin (hCG) hormone has been found in the
vaccines. It does not belong there -in the parlance of the O.J.
Simpson murder trial, the vaccine has been "contaminated."
* The vaccination protocols call for multiple injections-three within
three months and a total of five altogether. But, since tetanus
vaccinations provide protection for ten years or more, why are
multiple inoculations called for?
* WHO has been actively involved for more than 20 years in the
development of an anti-fertility vaccine utilizing hCG tied to
tetanus toxoid as a carrier-the exact same coupling as has been found
in the Mexican-Philippine-Nicaragua vaccines.
The anti-fertility gang
Allied with the WHO in the development of an anti-fertility vaccine
(AFV) using hCG with tetanus and other carriers have been UNFPA, the
UN Development Programme (UNDP), the World Bank, the Population
Council, the Rockefeller Foundation, the All India Institute of
Medical Sciences, and a number of universities, including Uppsala,
Helsinki, and Ohio State. The U.S. National Institute of Child
Health and Human Development (part of NIH) was the supplier of the
hCG hormone in some of the AFV experiments.
The WHO began its "Special Programme" in human reproduction in 1972,
and by 1993 had spent more than $356 million on "reproductive health"
research. It is this "Programme" which has pioneered the
development of the abortificant vaccine. Over $90 million of this
Programme's funds were contributed by Sweden; Great Britain donated
more than $52 million, while Norway, Denmark and Germany kicked in
for $41 million, $27 million, and $12 million, respectively. The
U.S., thanks to the cut-off of such funding during the Reagan-Bush
administrations, has contributed "only" $5.7 million, including a new
payment in 1993 by the Clinton administration of $2.5 million. Other
major contributors to the WHO Programme include UNFPA, $61 million;
the World Bank, $15.5 million; the Rockefeller Foundation, $2.5
million; the Ford Foundation, over $1 million; and the IDRC
(International Research and Development Centre of Canada), $716.5
WHO and Philippine Health Department excuses
When the first reports surfaced in the Philippines of tetanus toxoid
vaccine being laced with hCG hormones, the WHO and the Philippine
Department of Health (DOH) immediately denied that the vaccine
contained hCG. Confronted with the results of laboratory tests which
detected its presence in three of the four vials of tetanus toxoid
examined, the WHO and DOH scoffed at the evidence coming from
"right-to-life and Catholic" sources. Four new vials of the tetanus
vaccine were submitted by DOH to St. Luke's (Lutheran) Medical
Center in Manila-and all four vials tested positive for hCG!
From outright denial the stories now shifted to the allegedly
"insignificant" quantity of the hCG present; the volume of hCG
present is insufficient to produce anti-hCG antibodies.
But new tests designed to detect the presence of hCG antibodies in
the blood sera of women vaccinated with the tetanus toxoid vaccine
were undertaken by Philippine pro- life and Catholic groups. Of
thirty women tested subsequent to receiving tetanus toxoid vaccine,
twenty-six tested positive for high levels of anti-hCG antibodies! If
there were no hCG in the vaccine, or if it were present in only
"insignificant" quantities, why were the vaccinated women found to be
harboring anti-hCG antibodies? The WHO and the DOH had no answers.
New arguments surfaced: hCG's apparent presence in the vaccine was
due to "false positives" resulting from the particular substances
mixed in the vaccine or in the chemicals testing for hCG. And even if
hCG was really there, its presence derived from the manufacturing
But the finding of hCG antibodies in the blood sera of vaccinated
women obviated the need to get bogged down in such debates. It was no
longer necessary to argue about what may or may not have been the
<cause> of the hCG presence, when one now had the <effect> of the
hCG. There is no known way for the vaccinated women to have hCG
antibodies in their blood unless hCG had been artificially introduced
into their bodies!
Why a tetanus toxoid "carrier"?
Because the human body does not attack its own naturally occurring
hormone hCG, the body has to be fooled into treating hCG as an
invading enemy in order to develop a successful antifertility vaccine
utilizing hCG antibodies. A paper delivered at the 4th International
Congress of Reproductive Immunology (Kiel, West Germany, 2629 July
1989) spelled it out: "Linkage to a carrier was done to overcome the
immunological tolerance to hCG."
Vaccine untested by Drug Bureau
After the vaccine controversy had reached a fever pitch, a new
bombshell exploded: none of the three different brands of tetanus
vaccine being used had ever been licensed for sale and distribution
or registered with the Philippine Bureau of Food and Drugs (BFAD), as
required by law. The head of the BAFD lamely explained that the
companies distributing these brands "did not apply for
registration." The companies in question are Connaught
Laboratories Ltd. and Intervex, both from Canada, and CSL
Laboratories from Australia.
It seemed that the BAFD might belatedly require re-testing, but the
idea was quickly rejected when the Secretary of Health declared that,
since the vaccines had been certified by the WHO -there they are
again!-there was assurance enough that the "vaccines come from
Just how "reputable" one of the manufacturers might be is open to
some question. In the mid-'80s Connaught Laboratories was found to
be knowingly distributing vials of AIDS-contaminated blood
At this juncture, evidence is beginning to appear from Africa.
HLI has called for a Congressional investigation of the situation,
inasmuch as nearly every agency involved in the development of an
anti-fertility vaccine is funded, at least in part, with U.S.
1 "Abortifacient vaccines loom as new threat," <HLI Reports>,
November 1993, pp. 1-2.
2 <World Council Reports>, 28 November 1994, pp. 4-5.
3 A call placed by this writer on 5 May 1995 to the Montgomery County
(Maryland) Health Department, Epidemology Division-Infectious
Diseases - Adult Immunizations, elicited the following information:
Q. For how long a time does the tetanus vaccination offer protection?
A. 10 years.
Q. Have you ever heard of any adult requiring three tetanus
vaccinations within a 3 or 4 month time period, and a total of 5
vaccinations in all within a year or so?
A. Whaaaat! Never. No way!
Reports from the Philippines appear to confirm the 10-year immunity
afforded by tetanus toxoid vaccinations: prior to the campaigns begun
in 1993, the so-called booster shots were given only every 10-years.
4 More than a score of articles, many written by WHO researchers,
document WHO's attempts to create an anti-fertility vaccine utilizing
tetanus toxoid as a carrier. Some leading articles include:
"Clinical profile and Toxicology Studies on Four Women Immunized with
Pr-B-hCG- TT," <Contraception>, February, 1976, pp. 253-268.
"Observations on the antigenicity and clinical effects of a candidate
antipregnancy vaccine: ,B-subunit of human chorionic gonadotropin
linked to tetanus toxoid," <Fertility and Sterility>, October 1980,
"Phase I Clinical Trials of a World Health Organization Birth Control
Vaccine," <The Lancet>, 11 June 1988, pp. 1295-1298. "Vaccines for
Fertility Regulation," Chapter 11, pp. 177-198, <Research in Human
Reproduction, Biennial Report> (1986-1987), WHO Special Programme of
Research, Development and Research Training in Human Reproduction
(WHO, Geneva 1988).
"Anti-hCG Vaccines are in Clinical Trials," <Scandinavian Journal of
Immunology>, Vol. 36, 1992, pp. 123-126.
5 These institutional names are garnered from the journal articles
cited in the previous footnote.
6 <Lancet>, 11 June 1988, at p. 1296.
7 <Challenges in Reproductive Health Research, Biennial Report
1992-1993>, World Health Organization, Geneva, 1994, p. 186.
8 G.P. Talwar, et al, "Prospects of an anti-hCG vaccine inducing
antibodies of high affinity...(etc)," <Reproductive Technology> 1989,
Elsevier Science Publishers, 1990, Amsterdam, New York, p. 231.
9 3 DOH vaccines untested by BFAD," <The Philippine Star>, 4 April
1995, pp. 1, 12.
10 "BFAD junks re-testing of controversial shot," <Manila Standard> 7
April 1995; "DOH: Toxoid vaccines are safe," <The Philippine Star>. 7
11 "Ottawa got blood tainted by HIV." <Ottawa Citizen>, 4 April 1995.
12 A nearly two-year old communique from Tanzania tells a familiar
story: tetanus toxoid vaccinations, five in all, given only to women
aged 1545. Nigeria, too, may have been victimized; see <The Lancet>,
4 June 1988, p. 1273.
Taken from the June/July 1995 issue of "HLI Reports." To subscribe
contact: HLI Reports, 7845 Airpark Road, Suite E Gaithersburg, MD
Provided courtesy of:
Eternal Word Television Network
5817 Old Leeds Road
Irondale, AL 35210
Promotion of research in human reproduction: global needs and perspectives.
The WHO Special Programme of Research, Development and Research Training in Human Reproduction was established in 1972, to respond to a global expansion in research needs in human reproduction, especially in the area of fertility regulation. The Programme's limited resources come from voluntary contributions by governments and international agencies. The emphasis is always on the needs of developing countries. The Programme has to keep the field under continuous review, and to direct its limited resources to the major unmet needs. This paper presents, from a global perspective, the needs and priorities in the promotion of research in human reproduction. It is emphasized that research has to be backed up by political commitment and resources if it is to have an impact on reproductive health. The role of determinants of health, other than and beyond the medical services, has also to be recognized. Promotion of research in human reproduction, to serve developing country needs, has to move into two directions. One is the mobilization of a global effort to develop and test technologies, where the available technologies are not satisfactory to meet the needs and where the research is slackening. The second is the strengthening of in-country resources for research to deal with country-specific problems and to enable countries to utilize, to the best, available technologies.
Reproductive health includes 4 elements: fertility regulation, safe pregnancy and childbirth, infant and child health and survival, and safe sex. Indicators of lack of reproductive health are: infertility (60-80 million cases), lack of access to fertility regulation (500 million cases), 30-50 million induced abortions a year, 9.6 million infant deaths and 4.8 million under-5 deaths, 250 million cases of gonorrhea, 50 million cases of syphilis, and an estimated 50-100 million cases of AIDS by 1991. Unregulated human fertility is a threat to man's continued survival on earth; the population is now 5 billion and grows by 80 million a year. Moreover, the inequitable distribution of reproductive health is a violation of human rights; 76% of the population, 99% of maternal deaths, 95% of infant and child deaths, and 90% of population growth are in developing countries. Biomedical research can improve reproductive health only if it is supported by an adequate health delivery system, adequate resources, and political commitment. To ensure that these conditions are met, the World Health Organization is advocating "health systems research" to optimize country-specific health service delivery. Research priorities are determined by the magnitude of the need, the urgency of the need, and the degree to which the need for research is being met. The global need for research in reproductive health is greatest in the areas of fertility regulation and infertility. These needs must be met in 2 ways: by developing and testing technologies and by strengthening in-country resources for research in country-specific problems. The World Health Organization's Special Programme of Research, Development and Research Training in Human Reproduction was established in 1972 to respond to global research needs, especially in the area of fertility regulation. In the 1st phase of the Program the emphasis was on the development of new technology. In the 2nd phase emphasis was placed also on health systems research to ensure that available technology reached the target populations in developing countries. The Program's 1st priority is on research and testing of existing methods of fertility regulation; the 2nd priority is research on methods at an advanced state of development, such as once-a-month injectables, 2-6 monthly injectables, levonorgestrel-releasing vaginal rings, progesterone-releasing vaginal rings, antiprogestins and antifertility vaccines; the 3rd priority is on methods further back in the pipeline, such as male contraceptives. The Special Program's research activities are conducted by task forces, run by steering committees, composed of multidisciplinary, multinational teams. A major objective of the program is to strengthen research capabilities in developing countries, and to this end it furnishes training, equipment and supplies, and encouragement to participate in the research activities. It also recognizes the need for collaboration between countries.
- [Indexed for MEDLINE]
Tetanus vaccine may be laced with anti-fertility drug. International / developing countries.
[No authors listed]
A priest, president of Human Life International (HLI) based in Maryland, has asked Congress to investigate reports of women in some developing countries unknowingly receiving a tetanus vaccine laced with the anti-fertility drug human chorionic gonadotropin (hCG). If it is true, he wants Congress to publicly condemn the mass vaccinations and to cut off funding to UN agencies and other involved organizations. The natural hormone hCG is needed to maintain pregnancy. The hormone would produce antibodies against hCG to prevent pregnancy. In the fall of 1994, the Pro Life Committee of Mexico was suspicious of the protocols for the tetanus toxoid campaign because they excluded all males and children and called for multiple injections of the vaccine in only women of reproductive age. Yet, one injection provides protection for at least 10 years. The Committee had vials of the tetanus vaccine analyzed for hCG. It informed HLI about the tetanus toxoid vaccine. HLI then told its World Council members and HLI affiliates in more than 60 countries. Similar tetanus vaccines laced with hCG have been uncovered in the Philippines and in Nicaragua. In addition to the World Health Organization (WHO), other organizations involved in the development of an anti-fertility vaccine using hCG include the UN Population Fund, the UN Development Programme, the World Bank, the Population Council, the Rockefeller Foundation, the US National Institute of Child Health and Human Development, the All India Institute of Medical Sciences, and Uppsala, Helsinki, and Ohio State universities. The priest objects that, if indeed the purpose of the mass vaccinations is to prevent pregnancies, women are uninformed, unsuspecting, and unconsenting victims.
Post a Comment